Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Letizia Musumeci

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Clinical and Experimental Dermatology|June 27, 2025
Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World StudyFrancesca Barei, Stefano Macchi, Paolo Calzari, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Dermatology Practical & Conceptual|November 14, 2025
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Clinical and Experimental Dermatology|June 27, 2025
Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World StudyFrancesca Barei, Stefano Macchi, Paolo Calzari, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Dermatology Practical & Conceptual|November 14, 2025
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, et al.
Clinical and Experimental Dermatology|April 15, 2026
Dupilumab for Prurigo Nodularis: Real-World Outcomes Up to 104 Weeks from the DUPItaPN StudyMarina Talamonti, Edoardo Mortato, Alessandra Narcisi, et al.
Pageof 6